Pharmafile Logo

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genesis Research Group

Genesis Research Group empowers life science companies to innovate differently by fundamentally transforming the way they engage with research partners. Through the integration of robust stakeholder insights (RPR), data-agnostic expertise,…

View Profile

Havas Life London

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Springer Nature

Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote your approved branded drugs and medical devices to our audience…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that we attend each year.

View Profile

Company Details

New Jersey Headquarters, 24 N. Main St, Pennington, NJ, 08534, USA
855.662.6732

 Latest Content from PMHub 

New syndicated reports now available

Living with CD, PsO, IPF & PF-ILD 2023

Hyper-personalisation – The immediate future of pharma is personalised.

What does hyper-personalisation in Pharma look like?

Train your brain for success

In this episode of Impetus Digital‘s Fireside Chat series, Natalie Yeadon, Co-Founder and CEO of Impetus Digital sits down with Max Newlon, President of Brain Co. They discuss everything from...

Virtual Patient Steering Committee: A Customer Story

A French pharmaceutical team contacted Impetus Digital to help them establish a Virtual Steering Committee for patients with HIV/AIDS. They wanted to find a way to directly involve patients in...

Article: Could combating stigma increase the uptake of PrEP and finally end the HIV epidemic?

In this article we explore what more could be done by the pharmaceutical industry to help prevent the spread of HIV infection worldwide.

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Origins’ Solutions Offering Explained

Providing patient solutions that are wanted, needed, accessible, and fit for purpose can help companies to increase the value and success of their products and gain respect and recognition for...

Leveraging virtual tools to get the most out of hybrid congresses

Tips on how to optimize congress information-gathering...

Closing the Gaps in Telehealth

Anthony Capone, President of DocGo, shares how his company uses last-mile mobile health services and integrated medical transportation solutions to make healthcare more accessible for everyone, including underserved populations.To find...

Medscape Present Outcomes of Neurology Education at AAN 2023

Medscape had education outcomes on the brain for this year’s AAN conference in Boston.During the conference, Medscape presented 5 scientific posters describing the impact of continuing medical education in migraine,...